Mouse Models of Sjögren’s Syndrome with Ocular Surface Disease

Sjögren’s syndrome (SS) is a systemic rheumatic disease that predominantly affects salivary and lacrimal glands resulting in oral and ocular dryness, respectively, referred to as sicca symptoms. The clinical presentation of ocular dryness includes keratoconjunctivitis sicca (KCS), resulting from the...

Full description

Bibliographic Details
Main Authors: Sharmila Masli, Darlene A. Dartt
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/21/23/9112
_version_ 1797546145798422528
author Sharmila Masli
Darlene A. Dartt
author_facet Sharmila Masli
Darlene A. Dartt
author_sort Sharmila Masli
collection DOAJ
description Sjögren’s syndrome (SS) is a systemic rheumatic disease that predominantly affects salivary and lacrimal glands resulting in oral and ocular dryness, respectively, referred to as sicca symptoms. The clinical presentation of ocular dryness includes keratoconjunctivitis sicca (KCS), resulting from the inflammatory damage to the ocular surface tissues of cornea and conjunctiva. The diagnostic evaluation of KCS is a critical component of the classification criteria used by clinicians worldwide to confirm SS diagnosis. Therapeutic management of SS requires both topical and systemic treatments. Several mouse models of SS have contributed to our current understanding of immunopathologic mechanisms underlying the disease. This information also helps develop novel therapeutic interventions. Although these models address glandular aspects of SS pathology, their impact on ocular surface tissues is addressed only in a few models such as thrombospondin (TSP)-1 deficient, C57BL/6.NOD.<i>Aec1Aec2</i>, NOD.H2<sup>b</sup>, NOD.Aire KO, and IL-2Rα (CD25) KO mice. While corneal and/or conjunctival damage is reported in most of these models, the characteristic SS specific autoantibodies are only reported in the TSP-1 deficient mouse model, which is also validated as a preclinical model. This review summarizes valuable insights provided by investigations on the ocular spectrum of the SS pathology in these models.
first_indexed 2024-03-10T14:25:55Z
format Article
id doaj.art-1aae2d4d6e734562baa1660c60bc3059
institution Directory Open Access Journal
issn 1661-6596
1422-0067
language English
last_indexed 2024-03-10T14:25:55Z
publishDate 2020-11-01
publisher MDPI AG
record_format Article
series International Journal of Molecular Sciences
spelling doaj.art-1aae2d4d6e734562baa1660c60bc30592023-11-20T22:58:20ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-11-012123911210.3390/ijms21239112Mouse Models of Sjögren’s Syndrome with Ocular Surface DiseaseSharmila Masli0Darlene A. Dartt1Department of Ophthalmology, Boston University School of Medicine, Boston, MA 02118, USASchepens Eye Research Institute/Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USASjögren’s syndrome (SS) is a systemic rheumatic disease that predominantly affects salivary and lacrimal glands resulting in oral and ocular dryness, respectively, referred to as sicca symptoms. The clinical presentation of ocular dryness includes keratoconjunctivitis sicca (KCS), resulting from the inflammatory damage to the ocular surface tissues of cornea and conjunctiva. The diagnostic evaluation of KCS is a critical component of the classification criteria used by clinicians worldwide to confirm SS diagnosis. Therapeutic management of SS requires both topical and systemic treatments. Several mouse models of SS have contributed to our current understanding of immunopathologic mechanisms underlying the disease. This information also helps develop novel therapeutic interventions. Although these models address glandular aspects of SS pathology, their impact on ocular surface tissues is addressed only in a few models such as thrombospondin (TSP)-1 deficient, C57BL/6.NOD.<i>Aec1Aec2</i>, NOD.H2<sup>b</sup>, NOD.Aire KO, and IL-2Rα (CD25) KO mice. While corneal and/or conjunctival damage is reported in most of these models, the characteristic SS specific autoantibodies are only reported in the TSP-1 deficient mouse model, which is also validated as a preclinical model. This review summarizes valuable insights provided by investigations on the ocular spectrum of the SS pathology in these models.https://www.mdpi.com/1422-0067/21/23/9112Sjögren’s syndromelacrimal glandcorneaconjunctivainflammation
spellingShingle Sharmila Masli
Darlene A. Dartt
Mouse Models of Sjögren’s Syndrome with Ocular Surface Disease
International Journal of Molecular Sciences
Sjögren’s syndrome
lacrimal gland
cornea
conjunctiva
inflammation
title Mouse Models of Sjögren’s Syndrome with Ocular Surface Disease
title_full Mouse Models of Sjögren’s Syndrome with Ocular Surface Disease
title_fullStr Mouse Models of Sjögren’s Syndrome with Ocular Surface Disease
title_full_unstemmed Mouse Models of Sjögren’s Syndrome with Ocular Surface Disease
title_short Mouse Models of Sjögren’s Syndrome with Ocular Surface Disease
title_sort mouse models of sjogren s syndrome with ocular surface disease
topic Sjögren’s syndrome
lacrimal gland
cornea
conjunctiva
inflammation
url https://www.mdpi.com/1422-0067/21/23/9112
work_keys_str_mv AT sharmilamasli mousemodelsofsjogrenssyndromewithocularsurfacedisease
AT darleneadartt mousemodelsofsjogrenssyndromewithocularsurfacedisease